CA2264715A1 - Methods and compositions for the treatment of bone resorption disorders, including osteoporosis - Google Patents

Methods and compositions for the treatment of bone resorption disorders, including osteoporosis Download PDF

Info

Publication number
CA2264715A1
CA2264715A1 CA002264715A CA2264715A CA2264715A1 CA 2264715 A1 CA2264715 A1 CA 2264715A1 CA 002264715 A CA002264715 A CA 002264715A CA 2264715 A CA2264715 A CA 2264715A CA 2264715 A1 CA2264715 A1 CA 2264715A1
Authority
CA
Canada
Prior art keywords
cathepsin
activity
gene
bone
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
CA002264715A
Other languages
English (en)
French (fr)
Inventor
Bruce D. Gelb
Harold Chapman
Robert J. Desnick
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Brigham and Womens Hospital Inc
Icahn School of Medicine at Mount Sinai
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2264715A1 publication Critical patent/CA2264715A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA002264715A 1996-08-28 1997-08-28 Methods and compositions for the treatment of bone resorption disorders, including osteoporosis Withdrawn CA2264715A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/704,473 1996-08-28
US08/704,473 US5830850A (en) 1996-08-28 1996-08-28 Methods for the treatment of bone resorption disorders, including osteoporosis
PCT/US1997/015121 WO1998008494A1 (en) 1996-08-28 1997-08-28 Methods and compositions for the treatment of bone resorption disorders, including osteoporosis

Publications (1)

Publication Number Publication Date
CA2264715A1 true CA2264715A1 (en) 1998-03-05

Family

ID=24829667

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002264715A Withdrawn CA2264715A1 (en) 1996-08-28 1997-08-28 Methods and compositions for the treatment of bone resorption disorders, including osteoporosis

Country Status (6)

Country Link
US (1) US5830850A (https=)
EP (1) EP0961613A4 (https=)
JP (1) JP2002508737A (https=)
AU (1) AU4165797A (https=)
CA (1) CA2264715A1 (https=)
WO (1) WO1998008494A1 (https=)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5501969A (en) 1994-03-08 1996-03-26 Human Genome Sciences, Inc. Human osteoclast-derived cathepsin
IL117175A (en) * 1995-02-20 2005-11-20 Sankyo Co Osteoclastogenesis inhibitory factor protein
SK48198A3 (en) * 1995-10-30 1998-10-07 Smithkline Beecham Corp Cathepsin k molecule, a peptid being bonded to the hollow of active positon of cathepsin k, a composition, method for identification of inhibiting compound and inhibitors being competitively bonded to the active position of cathepsin k
WO1997016433A1 (en) * 1995-10-30 1997-05-09 Smithkline Beecham Corporation Protease inhibitors
US6586466B2 (en) 1995-10-30 2003-07-01 Smithkline Beecham Corporation Carbohydrazide-protease inhibitors
JP4268684B2 (ja) * 1997-09-24 2009-05-27 第一三共株式会社 骨代謝異常症の診断方法
US20030044399A1 (en) * 1998-12-23 2003-03-06 Smithkline Beecham Corporation Method of treatment
US20030144175A1 (en) * 1998-12-23 2003-07-31 Smithkline Beecham Corporation Protease inhibitors
WO2000061785A2 (en) * 1999-04-14 2000-10-19 Smithkline Beecham Corporation Polynucleotide and polypeptide sequences of monkey cathepsin k
US20040214889A1 (en) * 1999-07-31 2004-10-28 Smithkline Beecham Corporation Calcilytic compounds
US6770468B1 (en) 1999-09-14 2004-08-03 Genzyme Glycobiology Research Institute, Inc. Phosphodiester-α-GlcNAcase of the lysosomal targeting pathway
US6534300B1 (en) 1999-09-14 2003-03-18 Genzyme Glycobiology Research Institute, Inc. Methods for producing highly phosphorylated lysosomal hydrolases
WO2001034600A1 (en) 1999-11-10 2001-05-17 Smithkline Beecham Corporation Protease inhibitors
US6534498B1 (en) 1999-11-10 2003-03-18 Smithkline Beecham Corporation Protease inhibitors
JP2003513971A (ja) 1999-11-10 2003-04-15 スミスクライン・ビーチャム・コーポレイション プロテア−ゼ阻害剤
JP2001158736A (ja) * 1999-11-30 2001-06-12 Snow Brand Milk Prod Co Ltd 骨関節疾患の予防及び改善剤
EP2095817A1 (en) * 1999-12-07 2009-09-02 Rutgers, The State University Of New Jersey Therapeutic compositions and methods
AU2001243441B2 (en) * 2000-03-21 2004-11-25 Smithkline Beecham Corporation Protease inhibitors
AU2001272981A1 (en) * 2000-06-22 2002-01-02 Genaissance Pharmaceuticals, Inc. Haplotypes of the slc26a2 gene
US7332494B2 (en) * 2000-08-14 2008-02-19 Janssen Pharmaceutica, N.V. Method for treating allergies using substituted pyrazoles
EP1309591B1 (en) * 2000-08-14 2007-01-24 Ortho-McNeil Pharmaceutical, Inc. Substituted pyrazoles
US20070105841A1 (en) * 2000-08-14 2007-05-10 Breitenbucher J G Method for treating allergies using substituted pyrazoles
US6369032B1 (en) * 2000-09-06 2002-04-09 Ortho-Mcneil Pharmaceutical, Inc. Method for treating allergies
US20030073672A1 (en) * 2001-09-05 2003-04-17 Breitenbucher J. Guy Method for treating allergies using substituted pyrazoles
US7799326B2 (en) * 2001-09-24 2010-09-21 Mount Sinai School Of Medicine Methods and compositions for cathespin k complex-mediated disorders
US6800472B2 (en) 2001-12-21 2004-10-05 Genzyme Glycobiology Research Institute, Inc. Expression of lysosomal hydrolase in cells expressing pro-N-acetylglucosamine-1-phosphodiester α-N-acetyl glucosimanidase
US6905856B2 (en) 2001-12-21 2005-06-14 Genzyme Glycobiology Research Institute, Inc. Soluble GlcNAc phosphotransferase
US20040138162A1 (en) * 2002-08-30 2004-07-15 Roodman G. David Method of resisting osteoclast formation
US20040170621A1 (en) * 2002-08-30 2004-09-02 Roodman G. David Method of resisting osteoclast formation
EP1585750B1 (en) * 2002-12-09 2008-10-15 Arizona Board Of Regents Narcistatin prodrugs
US20060020001A1 (en) * 2002-12-23 2006-01-26 Allan Shepard Use of cathepsin k inhibitors for the treatment of glaucoma
WO2005089736A2 (en) * 2004-03-05 2005-09-29 The Arizona Board Of Regents, On Behalf Of, Arizona State University Methods for treating inflammatory and autoimmune diseases
WO2009076490A1 (en) * 2007-12-12 2009-06-18 Velcura Therapeutics, Inc. Use of cathepsin l antagonists in the treatment of bone disease
CN105456292B (zh) * 2009-10-30 2019-03-26 北卡罗来纳大学教堂山分校 来自肝外胆管树的专能干细胞及其分离方法
WO2013037770A1 (en) * 2011-09-15 2013-03-21 Bayer Intellectual Property Gmbh Method for the continuous production of water-dispersible vinyl polymers
NZ627896A (en) 2012-01-27 2016-11-25 Biomarin Technologies B V Rna modulating oligonucleotides with improved characteristics for the treatment of duchenne and becker muscular dystrophy

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4873191A (en) * 1981-06-12 1989-10-10 Ohio University Genetic transformation of zygotes
US4902505A (en) * 1986-07-30 1990-02-20 Alkermes Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US5116742A (en) * 1986-12-03 1992-05-26 University Patents, Inc. RNA ribozyme restriction endoribonucleases and methods
US4987071A (en) * 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
US5158936A (en) * 1986-12-22 1992-10-27 Syntex (U.S.A.) Inc. Aryloxy and arylacyloxy methyl ketones as thiol protease inhibitors
US4904582A (en) * 1987-06-11 1990-02-27 Synthetic Genetics Novel amphiphilic nucleic acid conjugates
ATE117375T1 (de) * 1987-09-11 1995-02-15 Whitehead Biomedical Inst Transduktionsveränderte fibroblasten und ihre anwendung.
US5399349A (en) * 1992-02-06 1995-03-21 Paunescu; Calin Treatment of acne
US5550138A (en) * 1992-03-25 1996-08-27 Takeda Chemical Industries, Ltd. Condensed thiadiazole derivative, method of its production, and use thereof
US5374623A (en) * 1992-08-20 1994-12-20 Prototek, Inc. Cysteine protease inhibitors effective for in vivo use
US5525623A (en) * 1993-03-12 1996-06-11 Arris Pharmaceutical Corporation Compositions and methods for the treatment of immunomediated inflammatory disorders
US5486623A (en) * 1993-12-08 1996-01-23 Prototek, Inc. Cysteine protease inhibitors containing heterocyclic leaving groups
IL112759A0 (en) * 1994-02-25 1995-05-26 Khepri Pharmaceuticals Inc Novel cysteine protease inhibitors
US5501969A (en) * 1994-03-08 1996-03-26 Human Genome Sciences, Inc. Human osteoclast-derived cathepsin
TW438591B (en) * 1995-06-07 2001-06-07 Arris Pharm Corp Reversible cysteine protease inhibitors

Also Published As

Publication number Publication date
AU4165797A (en) 1998-03-19
JP2002508737A (ja) 2002-03-19
US5830850A (en) 1998-11-03
EP0961613A1 (en) 1999-12-08
EP0961613A4 (en) 2003-07-23
WO1998008494A1 (en) 1998-03-05

Similar Documents

Publication Publication Date Title
CA2264715A1 (en) Methods and compositions for the treatment of bone resorption disorders, including osteoporosis
US5843641A (en) Methods for the daignosis, of familial amyotrophic lateral sclerosis
US6486299B1 (en) Genes and proteins predictive and therapeutic for stroke, hypertension, diabetes and obesity
US5861485A (en) Polypeptides involved in body weight disorders, including obesity
US5958769A (en) Compositions and methods for mediating cell cycle progression
US5853975A (en) Methods for identifying compositions for the treatment of body weight disorders, including obesity
WO2001042266A1 (en) Antisense modulation of amyloid beta protein expression
CA2341705A1 (en) Sequences characteristic of hypoxia-regulated gene transcription
JPH10500842A (ja) ユビキチン結合酵素をコードするｄｎａ
US5741666A (en) Compositions and methods, for the treatment of body weight disorders, including obesity
US7402724B2 (en) Longevity and PAPP-A
Chadwick et al. Cloning, mapping, and expression of two novel actin genes, actin-like-7A (ACTL7A) and actin-like-7B (ACTL7B), from the familial dysautonomia candidate region on 9q31
WO2000005373A2 (en) Methods and compositions for the diagnosis and treatment of body weight disorders, including obesity
AU735317B2 (en) Rath genes and polypeptides and methods for the treatment and diagnosis of immune disorders
WO2002058724A2 (en) Use of lp82 to treat body weight disorders
JP2001523467A (ja) 炎症性疾患のトランスジェニックモデル
WO1999041381A1 (en) Neuroserpin
CA2196190A1 (en) Ikaros transgenic cells and animals
US7973156B2 (en) Hypoxia-regulated genes
WO1998019671A1 (en) Methods and compositions for the treatment of bone resorption disorders, including osteoporosis
US5939316A (en) Chromosome 18 marker
CA2298474A1 (en) Methods and compositions for the diagnosis and treatment of neuropsychiatric disorders
US5846780A (en) Murine RATH gene
US7220892B2 (en) Transgenic mouse lacking PAPP-A activity
US20040162237A1 (en) Use of lp82 to treat body weight disorders

Legal Events

Date Code Title Description
EEER Examination request
AZWI Withdrawn application

Effective date: 20141017

AZWI Withdrawn application

Effective date: 20141017